1. Home
  2. Publications
  3. Figure 5 from Imaging Glioblastoma Response...

Figure 5 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism

Abstract:
<p><sup>13</sup>C MR spectra acquired following intravenous injection of hyperpolarized [1,4-<sup>13</sup>C<sub>2</sub>,2,3-<sup>2</sup>H<sub>2</sub>]fumarate. Summed spectra showing flux of hyperpolarized <sup>13</sup>C label between [1,4-<sup>13</sup>C<sub>2</sub>,2,3-<sup>2</sup>H<sub>2</sub>]fumarate (177.2 ppm) and [1,4-<sup>13</sup>C<sub>2</sub>,2,3-<sup>2</sup>H<sub>2</sub>]malate (182.2, 183.6 ppm) were acquired from an 8-mm tumor slice over a period of 180 seconds starting from the time of injection. Spectra were acquired from A11 (<b>A</b>), S2 (<b>C</b>), and U87 (<b>E</b>) tumors before and at 48 hours after the last chemo-radiotherapy session. Malate/fumarate signal ratios in A11 (<i>n</i> = 4, paired two-tailed <i>t</i> test; <b>B</b>), S2 (<i>n</i> = 4, paired two-tailed <i>t</i> test; <b>D</b>), and U87 (<i>n</i> = 3, paired two-tailed <i>t</i> test; <b>F</b>) tumors pre- and posttreatment. The ratios were obtained from the summed spectra. ns, nonsignificant.</p>
Article has an altmetric score of 89
Authors:
F Hesse, AJ Wright, V Somai, F Bulat, F Kreis, KM Brindle
Publication date:
24th Nov 2025
Full text
DOI